Company Cardium Therapeutics Inc Nyse
Equities
US1419161062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Lois Chandler
COO | Chief Operating Officer | - | 10-06-30 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 20-05-21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 20-05-21 |
Kaushik Vyas
BRD | Director/Board Member | 68 | 20-05-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 64,931,888 | 60,931,888 ( 93.84 %) | 0 | 93.84 % |
Stock B | 0 | 498 | 0 | 0 |
Company contact information
Taxus Cardium Pharmaceuticals Group, Inc.
11230 Sorrento Valley Road Suite 220
92121, San Diego
+858 414 1477
http://www.genebiotherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.45% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- CRXM Stock
- Stock
- Company Cardium Therapeutics Inc